clinical trial · NCT05676853
A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency
Aeglea Biotherapeutics·phase3·terminated·n = 3
Arginase I DeficiencyHyperargininemiaPegzilarginase
brief summary
This is an open-label, multicenter study to evaluate the safety of weekly SC administration of pegzilarginase over 12 months in subjects with ARG1-D. The study consists of a screening period of up to 4 weeks, a subsequent 12-month treatment period, and a Safety Follow-Up Visit 2 weeks after the last treatment.
started
Apr 4, 2023
primary completion
Apr 27, 2023
completion
Apr 27, 2023
last updated
Jul 27, 2023
detailed description
Open-label, multicenter study to evaluate the safety of weekly SC administration of pegzilarginase over 12 months in subjects with ARG1-D. The study consists of a screening period of up to 4 weeks, a subsequent 12-month treatment period, and a Safety Follow-Up Visit 2 weeks after the last treatment.
official title
A Phase 3 Open-Label Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol